Latest news with #QualityManagementSystem
&w=3840&q=100)
Business Standard
16-07-2025
- Business
- Business Standard
Asston Pharmaceuticals disappoints with market debut, lists at 3% discount
Asston Pharmaceuticals IPO listing today: Shares of healthcare products supplier Asston Pharmaceuticals made a poor debut on the BSE SME platform on Wednesday, July 16, following the completion of its Initial Public Offering (IPO). The stock listed at ₹119 per share, reflecting a discount of ₹4 or 3.25 per cent over the IPO issue price of ₹123. The Asston Pharmaceuticals IPO fell short of grey market expectations. Prior to the debut, its unlisted shares were trading at around ₹149 in the grey market, indicating a grey market premium (GMP) of ₹26 or approximately 21.14 per cent over the issue price, according to sources tracking unofficial market activity. Asston Pharmaceuticals IPO details The Asston Pharmaceuticals IPO comprised an entirely fresh issue of 2.24 million equity shares aggregating to ₹27.56 crore. The public offering was available for subscription from Wednesday, July 9, to Friday, July 11, at a price band of ₹115-123 per share, with a lot size of 1,000 shares. The public issue received overwhelming demand from investors, getting oversubscribed by 173.53 times by the end of the subscription period, as per BSE data. The basis of allotment for Asston Pharmaceuticals IPO shares was finalised on Monday, July 14. The company has fixed the issue price at ₹123 per share. Asston Pharmaceuticals will utilise the proceeds from its public issue to fund capital expenditure requirements, specifically for acquiring machinery for its manufacturing unit. A portion of the funds will also be allocated towards meeting the company's incremental working capital needs. Additionally, the proceeds will be used for the repayment and/or prepayment, either in part or in full, of certain outstanding borrowings. The remaining funds will be directed towards general corporate purposes. About Asston Pharmaceuticals Asston Pharmaceuticals specialises in exporting pharmaceuticals globally. The company offers a diverse range of products, including tablets, capsules, and syrups, across various therapeutic categories. Asston Pharmaceuticals is FDA-certified and complies with Quality Management System standards. The company's product portfolio includes medications for pain relief, infections, and vitamin deficiencies.
Economic Times
16-07-2025
- Business
- Economic Times
Asston Pharmaceuticals IPO to list today. GMP signals healthy premium on debut
Live Events Financial Snapshot (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Pharmaceutical exporter Asston Pharmaceuticals is all set to debut on the BSE SME platform on Wednesday with strong retail and institutional participation boosting pre-listing sentiment. The company's Rs 27.56 crore IPO, which was open between July 9 and 11, is commanding a grey market premium (GMP) of Rs 30, translating to a 24% premium over the issue price of Rs 123 per IPO was entirely a fresh issue of 22.41 lakh in 2019, Asston Pharmaceuticals manufactures and exports a wide range of pharmaceutical formulations, including tablets, syrups, capsules, and company focuses on key therapeutic categories such as analgesics, antibiotics, antifungals, and vitamins, with products like Albendazole, Diclofenac, and Ferrovit Syrup forming part of its operates on both direct sales and contract manufacturing models and holds certifications from central and state FDA, NQA, and follows Quality Management System (QMS) standards. As of July 2025, it has a workforce of 52 employees, including 6 on company posted robust growth in FY25, with revenue up 62% year-on-year to Rs 25.61 crore, and PAT rising 218% to Rs 4.33 crore. EBITDA also jumped to Rs 6.16 crore from Rs 2.55 crore in the previous a 24% GMP, strong financials, and growing demand for Indian pharma exports, Asston's listing is expected to see healthy investor interest, though the SME segment's volatility remains a caveat. All eyes will now be on the stock's opening tick on Wednesday.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Yahoo
16-06-2025
- Business
- Yahoo
AgEagle Switzerland Facility Recommended for Prestigious ISO 9001 Certification
Achievement demonstrates manufacturer's drive for excellence in drone production Cheseaux-sur-Lausanne, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:UAVS), a leading provider of advanced drone and aerial imaging solutions, is proud to announce their Switzerland facility has been recommended to receive ISO 9001 certification by third-party auditors following an intensive review of the facilities Quality Management System. This prestigious certification reflects AgEagle's commitment to excellence, safety, and innovation. The ISO 9001 standard is widely recognized across all industries and sets rigorous requirements for quality management, customer satisfaction, risk mitigation, safety, and continuous improvement. Earning this certification for the Switzerland facility—home to key research, development, and manufacturing of AgEagle's cutting-edge drone technologies—demonstrates: Unmatched Quality Assurance: The facility meets the highest industry standards for producing reliable drone systems, such as the eBee TAC Public Safety drone and the eBee VISION drone, ensuring precision and performance for worldwide customers. Operational Excellence: The process highlights AgEagle's dedication to streamlining production and maintaining safety, supporting sustainable farming innovations and bringing new technologies to market Enhanced Global Trust: Certification strengthens AgEagle's credibility with international clients, including governments and procurement agencies, aligning with the company's growth into Intelligence, Surveillance and Reconnaissance (ISR) marketplaces and public safety operators. 'This significant achievement is a result of a tremendous amount of hard work and dedication from our Switzerland team,' said Bill Irby, CEO of AgEagle. 'Earning ISO 9001 certification is a clear indicator of commitment and quality, and it sets AgEagle apart. This validates our quality processes and positions us to meet the stringent demands of our worldwide customer base. I'm proud of the team, and we will lead the way in delivering trusted solutions.' The AgEagle Switzerland facility's certification enhances AgEagle's ability to continue serving existing customers at a high level, expand into additional markets and industries, and compete for more government tenders. 'This globally recognized standard opens doors to new opportunities, as many government agencies in defense, aerospace, and technology sectors require ISO 9001 compliance to bid on tenders. By meeting these rigorous quality management criteria, we're well-positioned to expand our impact in public sector markets around the globe,' said Irby. For more information about AgEagle Aerial Systems, visit or contact media@ ### About AgEagle Aerial Systems Inc. Through its three Centers of Excellence, AgEagle is actively engaged in designing and delivering best-in-class flight hardware, sensors and software that solve important problems for its customers. Founded in 2010, AgEagle was originally formed to pioneer proprietary, professional-grade, fixed-winged drones and aerial imagery-based data collection and analytics solutions for the agriculture industry. Today, AgEagle is a leading provider of full stack UAS, sensors and software solutions for customers worldwide in the energy, construction, agriculture, and government verticals. For additional information, please visit our website at Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on AgEagle's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future purchase orders relating to AgEagle's products, the success of new programs and software updates, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AgEagle in general, see the risk disclosures in the Annual Report on Form 10-K of AgEagle for the year ended December 31, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by AgEagle. All such forward-looking statements speak only as of the date they are made, and AgEagle undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. -###- Media ContactAndy Woodward+1 (469) LinkedIn Facebook X YouTube Investor RelationsEmail: UAVS@
Yahoo
16-06-2025
- Health
- Yahoo
Medical Device Non-Conformance and Corrective Action for Manufacturers Training Course: Learn ISO 13485 and 21 CFR 820 Standards on Non-conformance Management (ONLINE EVENT: July 18, 2025)
Enhance your understanding of medical device Quality Management Systems (QMS) with our regulatory course. , CAPA processes, and root cause analysis to boost compliance and performance. Part of our Regulatory Affairs Training series. Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Non-Conformance and Corrective Action for Medical Device Manufacturers Training Course" training has been added to offering. This course provides an introduction to these regulatory requirements as they relate to the identification and handling of non-conformances and how manufacturers may demonstrate compliance. The identification of non-conformances and ensuring that they are dealt with in a timely and appropriate manner is a key part of any medical device Quality Management System (QMS). Regulations for medical device quality management systems include particular requirements for non-conformance, correction, corrective and preventative actions. These requirements relate to non-conformances identified through internal audits, external audits, routine processes, customer complaints vigilance and many other activities. Evidence of a QMS which deals with non-conformance and prevents recurrence is important and expected when demonstrating conformity with the regulations. These requirements are defined in ISO 13485, the international standard for medical device quality management systems, as well as in 21 CFR 820 and other global regulations. Benefits of Attending Understand the sources of non-conformance within a medical device QMS Learn techniques to establish the root cause of a non-conformance Understand the difference between containment, correction, corrective action, and preventative action Gain an awareness of the ways in which an effective Corrective and Preventative Action (CAPA) system can lead to improved performance and regulatory compliance Who Should Attend: Managers and supervisors working within a regulated Quality Management System (QMS) Regulatory Compliance specialists Quality Management System (QMS) specialists Internal Auditors Regulatory and Quality professionals Certification: CPD: 3 hours for your records Certificate of completion Key Topics Covered: Non-Conformance and Corrective Action Regulatory requirements for non-conformance and corrective action Definitions and understanding CAPA Sources of non-conformance and writing an effective statement of non-compliance The non-conformance and corrective action cycle Assessment of the risk associated with non-compliance Root cause analysis tools and methodology Correction, containment and impact assessment Taking effective corrective action to address root causes Evaluation of the effectiveness of corrective action Use of electronic quality management systems for non-conformance management Preventive Action Regulatory requirements for identification of preventive action Sources of preventive action and how to capture the details Root cause analysis Evaluation of the effectiveness of preventive action For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
13-05-2025
- Automotive
- Time of India
Revolt Motors secures ISO Certification for quality management
Indian electric motorcycle manufacturer, Revolt Motors , has received ISO 9001:2015 certification for its Quality Management System (QMS). The certification, issued by an international testing and certification body, confirms that the company meets global standards in product design, production, supply chain, and customer service. ISO 9001:2015 is an internationally recognised standard for quality management systems and is granted to organisations that demonstrate compliance with specific quality benchmarks. Structured approach and strategic plans Anjali Rattan Nashier, Chairperson, RattanIndia Enterprises, said, 'This certification is a proud moment for all of us at R ev olt. It is a reflection of our tireless pursuit of quality, innovation, and operational excellence. As we expand to new geographies and strengthen our position in the EV segment, this global certification reinforces the trust our customers and partners place in us.' Revolt's certification highlights its structured processes in product development, manufacturing controls, and customer-focused delivery. The company states that the certification aligns with its long-term strategy, which includes international expansion and enhancing after-sales service. The company noted that the certification supports its credibility among business partners, collaborators, and institutional stakeholders. It applies across its product range, from the RV400 to the BlazeX.
